Innovation & intellectual property · 04/10/2021Updated: 10/17/2026 · 1 min read
U.S. Patent Office Grants Interim Extension to ECI Cancer Immunotherapy Patent
Summary
The U.S. Patent and Trademark Office has issued a one-year extension to the term of U.S. Patent No. 6,406,699, allowing ECI Cancer Immunotherapy to continue using its technology for an additional year.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →